Sanjeevaiah Aravind, Park Haeseong, Fangman Benjamin, Porembka Matthew
Department of Medicine, University of Texas at Southwestern, Dallas, TX 75390, USA.
Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
Cancers (Basel). 2020 Mar 5;12(3):592. doi: 10.3390/cancers12030592.
Gastric adenocarcinoma is an aggressive cancer that demonstrates heterogeneous biology depending on patient ethnicity, tumor location, tumor type, and genetic profile. It remains the third leading cause of cancer deaths worldwide and was estimated to result in 782,000 deaths in 2018. Challenges exist in accurately assessing the disease burden, as available radiological staging often underestimates metastatic disease. This diagnostic handicap, along with the poor understanding of the heterogeneous biology of gastric cancer, has hindered the development of effective therapeutic solutions and thus halted improvement in patient outcomes over the last few decades. The management of occult peritoneal disease is complicated, as most patients are understaged by standard imaging studies and therefore thought to have local diseases. In this article, we systematically review recent literature on the limitations that are associated with standard radiographic staging, discuss recent molecular biology advances to better identify and diagnose occult peritoneal disease, and propose possible management strategies to approach this complicated clinical problem.
胃腺癌是一种侵袭性癌症,其生物学特性因患者种族、肿瘤位置、肿瘤类型和基因谱而异。它仍然是全球癌症死亡的第三大主要原因,据估计2018年导致了78.2万人死亡。准确评估疾病负担存在挑战,因为现有的放射学分期往往低估转移性疾病。这种诊断障碍,加上对胃癌异质性生物学的了解不足,阻碍了有效治疗方案的开发,从而在过去几十年中阻碍了患者预后的改善。隐匿性腹膜疾病的管理很复杂,因为大多数患者通过标准影像学检查分期不足,因此被认为患有局部疾病。在本文中,我们系统地回顾了近期关于与标准放射学分期相关的局限性的文献,讨论了近期分子生物学进展以更好地识别和诊断隐匿性腹膜疾病,并提出了处理这一复杂临床问题的可能管理策略。